Recently, Gabai-Kapara and coworkers have performed a population-based screening for ovarian cancer risk due to BRCA1 and BRCA2 in the Ashkenazi Jewish population of Israel; it was estimated that in this population 40% of ovarian cancers are due to BRCA1 and BRCA2 mutations. This evidence concerns the gene BRCA2 and ovarian cancer.